详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective

93| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

出处：

DOI：

ISSN：

关键词： glycyrrhizin chimeric antigen receptor T-cell therapy cytokine release syndrome tocilizumab corticosteroids

摘要：

Chimeric antigen receptor T (CAR T)-cell therapy promises to revolutionize the management of hematologic malignancies and possibly other tumors. However, the main side effect of cytokine release syndrome (CRS) is a great challenge for its clinical application. Currently, treatment of CRS caused by CAR T-cell therapy is limited to tocilizumab (TCZ) and corticosteroids in clinical guidelines. However, the theoretical risks of these two agents may curb clinicians' enthusiasm for their application, and the optimal treatment is still debated. CAR T-cell therapy induced-CRS treatment is a current research focus. Glycyrrhizin, which has diverse pharmacological effects, good tolerance, and affordability, is an ideal therapeutic alternative for CRS. It can also overcome the shortcoming of TCZ and corticosteroids. In this brief article, we discuss the therapeutic potential of glycyrrhizin for treating CRS caused by CAR T-cell therapy from the perspective of its pharmacological action.Copyright © 2023 Qi, Li and Luo.

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区

医学

小类 | 2 区药学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区药学

JCR分区：

出版当年[2021]版：

Q1 PHARMACOLOGY & PHARMACY

最新[2023]版：

Q1 PHARMACOLOGY & PHARMACY

影响因子： 4.4 最新[2023版] 5 最新五年平均 5.988 出版当年[2021版] 6.455 出版当年五年平均 5.811 出版前一年[2020版] 5.6 出版后一年[2022版]

第一作者：

第一作者单位： [1]Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies [2]Macrophage, the potential key mediator in CAR-T related CRS [3]Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas [4]Patients' experience with chimeric antigen receptor T-cell therapy for DLBCL in China: a qualitative study [5]Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy [6]Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients [7]The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook [8]Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future [9]Anti-CD30 Chimeric Antigen Receptor T Cell Therapy for CD30+ Relapsed/Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients [10]Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19